Phase 2 Ovarian Carcinoma Clinical Trials
29 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 29 trials
Recruiting
Phase 2
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
Ovarian CancerOvarian Cancer Metastatic RecurrentOvarian Cancer (OvCa)+1 more
Yonsei University116 enrolled1 locationNCT07340164
Recruiting
Phase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494
Recruiting
Phase 1Phase 2
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic40 enrolled3 locationsNCT05920798
Recruiting
Phase 2
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Ovarian CancerOvarian CarcinomaFallopian Tube Cancer+7 more
Memorial Sloan Kettering Cancer Center86 enrolled7 locationsNCT06290193
Recruiting
Phase 2
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+12 more
Roswell Park Cancer Institute60 enrolled1 locationNCT04919629
Recruiting
Phase 2
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Platinum-Sensitive Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Fallopian Tube Carcinoma+12 more
Roswell Park Cancer Institute80 enrolled2 locationsNCT05231122
Recruiting
Phase 1Phase 2
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 2
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Stage IV Ovarian Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8+3 more
Mayo Clinic43 enrolled1 locationNCT05465941
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled84 locationsNCT06172478
Recruiting
Phase 1Phase 2
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Ovarian CarcinomaNSCLCSCLC+5 more
Jacobio Pharmaceuticals Co., Ltd.152 enrolled1 locationNCT04686682
Recruiting
Phase 2
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Breast CarcinomaUrothelial CarcinomaOvarian Carcinoma+26 more
Mayo Clinic27 enrolled1 locationNCT07285044
Recruiting
Phase 2
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT
Small Cell Ovarian Carcinoma
ARCAGY/ GINECO GROUP27 enrolled13 locationsNCT04602377
Recruiting
Phase 1Phase 2
NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer
Ovarian CarcinomaEpithelial Ovarian Cancer
Radboud University Medical Center10 enrolled1 locationNCT05773859
Recruiting
Phase 2
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Ovarian CancerCervical CancerEndometrial Cancer+5 more
Dana-Farber Cancer Institute32 enrolled2 locationsNCT06677190
Recruiting
Phase 1Phase 2
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Platinum-refractory Ovarian Carcinoma
TILT Biotherapeutics Ltd.29 enrolled3 locationsNCT05271318
Recruiting
Phase 2
Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
Advanced Ovarian CarcinomaAdvanced Fallopian Tube CarcinomaAdvanced Primary Peritoneal Carcinoma+15 more
Mayo Clinic78 enrolled3 locationsNCT06639074
Recruiting
Phase 2
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Ovarian High Grade Serous AdenocarcinomaPlatinum-Resistant Ovarian Carcinoma
Emory University28 enrolled1 locationNCT05998135